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Abstract
Background: Supplementation with essential amino acids (EAAs) + arginine is a promising
nutritional approach to decrease plasma triglyceride (TG) concentrations, which are an
independent risk factor for ischemic heart disease.
Objective: The objective of this study was to examine the effects of 8 wk of EAA supplementation
on skeletal muscle basal metabolite concentrations and changes in metabolic response to acute
EAA intake, with an emphasis on mitochondrial metabolism, in adults with elevated TGs to better
understand the mechanisms of lowering plasma TGs.
Methods: Older adults with elevated plasma TG concentrations were given 22 g EAAs to ingest
acutely before and after an 8-wk EAA supplementation period. Skeletal muscle biopsy samples
were collected before and after acute EAA intake, both pre- and postsupplementation (4 biopsy
samples), and targeted metabolomic analyses of organic acids and acylcarnitines were conducted
on the specimens.
Results: Acute EAA intake resulted in increased skeletal muscle acylcarnitine concentrations
associated with oxidative catabolism of the supplement components, with the largest increases
found in acylcarnitines of branched-chain amino acid oxidative catabolism, including isovaleryl-
carnitine (2200%) and 2-methylbutyryl-carnitine (2400%). The chronic EAA supplementation
resulted in a 19% decrease in plasma TGs along with accumulation of long-chain acylcarnitines
myristoyl- (90%) and stearoyl- (120%) carnitine in skeletal muscle and increases in succinyl-
carnitine (250%) and the late-stage tricarboxylic acid cycle intermediates fumarate (44%) and
malate (110%).
Conclusions: Supplementation with EAAs shows promise as an approach for moderate reduction in
plasma TGs. Changes in skeletal muscle metabolites suggest incomplete fatty acid oxidation and
increased anaplerosis, which suggests a potential bottleneck in fatty acid metabolism. Curr Dev
Nutr 2017;1:e002071.
Introduction
Hypertriglyceridemia is a significant independent risk factor for ischemic heart disease,
which is the single largest killer of men and women in the United States (1). Hypertri-
glyceridemia prevalence increases with age and is associated with obesity, renal dis-
ease, and diabetes (2). The treatment of elevated TGs is included in the Adult Treatment
Panel III of the National Cholesterol Education Program (3, 4). Revising dietary mac-
ronutrient intake is a primary strategy for reducing TGs. Although limiting intake of
SFAs, trans FAs, and cholesterol is widely advocated to lower TGs, it is also well established
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that higher-carbohydrate diets increase plasma TG concentrations
(5) and low-carbohydrate diets have been found to reduce plasma
TGs more than low-calorie, low-fat diets (6). Because a reduction
in dietary carbohydrate is often accompanied by an increase in
protein intake, and the independent impact of these 2 factors
on plasma TG concentrations may be difficult to differentiate,
it is interesting to note that dietary supplementation of a diet
provided ad libitum with protein results in a lowering of plasma
TGs (7). The influence of amino acid intake on plasma lipid con-
centrations is largely unknown and is an active area of research
(8–10) to better isolate the effects of protein intake on lipid
concentrations.
In our previous studies in older adults with impaired glucose
tolerance, we observed decreased circulating and tissue TG con-
centrations after supplementing the diet with a small quantity of
essential amino acids (EAAs) + arginine (;22 g/d) between meals
for 16 wk (9). In another study, we found that a combination sup-
plement consisting of EAAs with whey protein and phytosterols
reduced plasma cholesterol and TG concentrations in overweight
people with mild hyperlipidemia (10). Others have found that
obese people exhibit alterations in skeletal muscle metabolism of
amino acids and FAs relative to lean people (11), with evidence
of increased anaplerosis and limited FA oxidative flux. A recent
study reported the coexistence of elevated short- and medium-
chain acylcarnitines and reduced branched-chain ketoacids and
tricarboxylic acid (TCA) cycle intermediates in skeletal muscle
from people with insulin resistance, suggesting that impaired
skeletal muscle metabolism of BCAAs and lipids may play a role in
the mechanisms underlying reduced insulin sensitivity (12).
This important link between FA and EAA oxidative metabolism
is tied to mitochondrial function where the oxidative fate of these
classes of molecules ultimately resides through b-oxidation and
entrance into the TCA cycle (13, 14). In fact, there is in vitro evi-
dence for a “branched-chain” carnitine-acylcarnitine translocase
in the mitochondria implicated in BCAA oxidative metabolism
(15). Increasing oxidative flux through BCAA pathways within
cultured skeletal muscle cells has been shown to effect a signifi-
cant increase in FA oxidation, with the implication that obstruc-
tions to BCAA oxidation could limit skeletal muscle lipid turnover
(12). To better understand this relation and to inform future nu-
tritional interventions in hypertriglyceridemia, we investigated
the effects of EAAs 1 arginine supplementation on mitochondrial
metabolism.
Methods
Reagents and chemicals
LC mobile phases consisting of HPLC-grade acetonitrile and the
modifiers formic acid and heptafluorobutyric acid were purchased
from Sigma-Aldrich, whereas water was generated by using an in-
house Milli-Q water purification system. Other chemicals, including
O-benzylhydroxylamine (OBHA), 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide, ethyl acetate, and methanol, were also purchased from
Sigma-Aldrich. Internal standards for targetedmetabolomics, including
sodium lactate 13C3, citric D4 (2,2,4,4) acid, fumaric
13C4 acid, sodium
pyruvate 13C3, a-ketoglutaric D6 acid, butyryl-l-carnitine D3, propionyl-
l-carnitine D3, acetyl-l- carnitine D3, decanoyl-l-carnitine D3, hexanoyl-
l-carnitine D3, isovaleryl-l-carnitine D9, octadecanoyl-l-carnitine
D3, octanoyl-l-carnitine D3, and tetradecanoyl-l-carnitine D3, were
purchased from Isotec (Sigma-Aldrich), whereas succinic D6 acid
and disodium-2-hydroxy-glutarate D3 (2,3,3) were purchased from
CDN Isotopes.
Participant information and experimental protocol
A total of 6 older [mean6 SD age: 696 4 y; BMI (in kg/m2): 356 9]
volunteers (4 women, 2 men) with elevated plasma TGs (2.3 6
0.4 mmol/L) participated in an 8-wk study period (Figure 1). Exclu-
sion criteria included diabetes, evidence of renal or liver disease,
bleeding disorders, endocrine disease (excluding well-controlled
hypothyroidism), and alcohol or drug abuse. Before beginning
the study, the participants were counseled to maintain their typ-
ical dietary intake and physical activity pattern. During the par-
ticipants’ study visits and in telephone calls between visits, they
were asked about dietary changes and reminded to not make any
changes. Before and after an 8-wk EAAs 1 arginine supplemen-
tation phase, participants underwent an acute EAAs 1 arginine
intake experiment wherein they arrived after an overnight fast
and a basal muscle biopsy sample was collected from the vastus
lateralis as described elsewhere (16), before consuming 1 g of
an EAA 1 arginine supplement dissolved in water every 10 min
for the next 3.5 h (22 g EAAs plus arginine in total). The composition
of the EAAs was as follows: 3.26% histidine, 8.57% isoleucine,
35.88% leucine, 17.08% lysine-hydrochloride, 3.59% methionine,
4.65% phenylalanine, 9.57% threonine, 7.44% valine, and 9.97% argi-
nine. The EAAs 1 arginine mixture was provided by Ajinomoto.
Upon completion of the acute EAAs1 arginine intake, another mus-
cle biopsy was taken. During the chronic supplementation phase,
participants ingested two 11-g doses/d in capsule form; one dose
between breakfast and lunch and the other dose between lunch
and dinner. The participants recorded their doses in a diary and
visited the hospital to receive a new supply of supplements
every 2 wk. The protocol was approved by the Institutional Re-
view Board at the University of Arkansas for Medical Sciences,
and informed consent was obtained from all individuals partici-
pating in the study. All procedures performed in studies involving
human participants were in accordance with the ethical standards
of the institutional or national research committee andwith the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
FIGURE 1 Overview of EAAs 1 arginine supplementation
experiment. An acute EAAs 1 arginine-ingestion (3.5 h) study was
held before (week 0) and after (week 8) a chronic EAAs 1 arginine
supplementation period. EAA, essential amino acid.
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Sample preparation
Skeletal muscle preparation. A portion of the skeletal muscle
biopsy samples were snap-frozen immediately after collection and
stored at 2808C until the study was complete. The samples were
batch-processed to minimize variation and were processed along-
side a set of standard porcine muscle samples to assess the presence
of experimental error. A more complete description of sample pro-
cessing for the skeletal muscles is outlined elsewhere (17). Briefly,
;15–25 mg frozen skeletal muscle was weighed and then trans-
ferred to a prechilled stainless steel homogenization tube loaded
with silicon carbide sharp particles (Biospec Products). Prechilled
50:50 methanol:water extraction buffer was added to each tube
at a ratio of 13 mL buffer/mg tissue and then a mixture of isotope-
labeled standards for organic acids and acylcarnitines was added
to each tube (see Supplemental Tables 1 and 2 for isotope standard
details). Samples were then homogenized by using a Bead Ruptor 24
(Omni International, Inc.) with the use of two 30-s homogenization
steps at 6.3 m/s with a subsequent dry ice cool-down step in be-
tween. Samples were centrifuged for 10 min at 14,000 3 g at 48C,
and the raw extract supernatant was transferred to a fresh tube
and stored at 2808C until subsequent analysis.
Organic acid sample preparation. An aliquot of the raw skeletal
muscle extract was derivatized as described elsewhere (18).
Briefly, 100 mL muscle extract was mixed with 50 mL of 1-M
OBHA (in pyridine buffer, pH 5.1) followed by the addition of
50 mL of 1-M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(in pyridine buffer, pH 5.1). The mixtures were shaken at room
temperature for 1 h, then extracted with ethyl acetate 3 times.
The combined organic layers were dried by SpeedVac (Thermo
Fisher) and then reconstituted in mobile phase (as described be-
low) and transferred to a vial for chromatography measurements.
Acylcarnitine sample preparation. Full details of the acylcarni-
tine preparation are described elsewhere (19). Briefly, aliquots
of the skeletal muscle raw extract were transferred to tubes,
dried by SpeedVac, and reconstituted in 0.1% phosphoric acid.
Acylcarnitineswere then loaded ontoOasisMCXextraction cartridges
FIGURE 2 Box plots showing skeletal muscle AC concentrations before (white boxes) and after (dark-gray boxes) acute EAAs 1 arginine
intake at weeks 0 and 8 of daily EAAs 1 arginine supplementation; n = 6. ACs shown are intermediates of EAA oxidative metabolism. Solid
horizontal lines within the boxes represent the median values. *P, 0.05, **P, 0.01, and ***P, 0.001 (paired t test). AC, acylcarnitine; EAA,
essential amino acid; 3OH, 3-hydroxy.
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(Waters Corp.) and activated by methanol immediately before
sample loading. Cartridges were washed twice with 0.1% phos-
phoric acid before samples were eluted with methanol. Eluates
were dried by SpeedVac, reconstituted in mobile phase (as de-
scribed below), and transferred to a vial for chromatography.
Chromatography MS
All LC-MS/MS procedures were conducted with an ABSciex Qtrap
5500 mass spectrometer with an Eksigent Micro 200 LC and con-
trolled by Analyst 1.6.3 software (Sciex, Inc.). Organic acid OBHA
derivatives were separated by using a 0.3- 3 150-mm ChromXP
C18EP column with a 3-mm particle size and 300-A˚ pore size (Eksi-
gent; Sciex, Inc.). Mobile phases for organic acid analysis consisted
of Milli-Q water with 1% formic acid (A) and acetonitrile with 1%
formic acid (B). The chromatographic elution program for organic
acids was operatedwith a flow rate of 25mL/min and began by hold-
ing the mobile phase at 25% B for 30 s, followed by a linear gradient
to 70% B for 5 min, then a 30 s linear gradient to 100% B, where it
was held for a final 30 s. Acylcarnitines were separated on a 0.5- 3
150-mm Halo C18 column with a 2.7-mm particle size and a 90-A˚
pore size (Eksigent; Sciex, Inc.). The mobile phases for acylcarnitine
analysis consisted of Milli-Q water with a 0.08% heptafluorobutyric
acid ion-pairing agent (A) and acetonitrile (B). The elution program
for acylcarnitines was run at 25 mL/min by using a stepped gradient
profile from 5% B to 95% B over 10 min (see Supplemental Tables
1 and 2 for more details). MS was conducted by using multiple reac-
tion monitoring (MRM) following the settings as described in the
Supplemental Information. Sample concentrationswere determined
by using MRM peak ratios with internal standards as described in
Supplemental Tables 1 and 2.
Data analysis
MRM peak areas were measured by using Analyst 1.6.4 software
and MultiQuant and were visually inspected. Muscle sample
masses and chromatographic peak areas of analytes and isotope stan-
dards were imported into R software for statistical analysis. Mass
concentrations of analytes were calculated in terms of analyte
mass per milligram of muscle tissue. Grubb’s test for outliers
(a = 0.05) was performed on participants’metabolite concentra-
tion response to both the acute EAAs 1 arginine challenge and
the 8-wk EAAs 1 arginine supplementation. Nine of 576 meta-
bolic responses measured were determined to be outliers by
the Grubb’s test and removed from the analysis. Statistical anal-
ysis was conducted by using paired t tests (a = 0.05) to compare
each participant’s basal concentrations for skeletal muscle me-
tabolites before and after the 8-wk supplementation period.
Paired t tests were also conducted to compare skeletal muscle
metabolite concentrations before and after the periods of acute
EAAs 1 arginine intake.
FIGURE 3 Measured acylcarnitine species within catabolic
pathways of amino acids present in EAA supplementation and
anaplerotic routes into the TCA cycle through acetyl-CoA or
succinyl-CoA. EAA, essential amino acid; TCA, tricaboxylic acid; 3-
OH, 3-hydroxy.
FIGURE 4 Box plots showing skeletal muscle AC concentrations before (white boxes) and after (dark-gray boxes) acute EAAs 1 arginine
intake at weeks 0 and 8 of daily EAAs 1 arginine supplementation; n = 6. ACs shown are intermediates of EAA oxidative metabolism. Solid
horizontal lines within the boxes represent the median values. #P , 0.06, *P , 0.05, and **P , 0.01 (paired t test). AC, acylcarnitine; EAA,
essential amino acid.
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Results
Plasma TG concentrations
After 8wkof EAAs1 arginine supplementation, fasted plasmaTGcon-
centrationswere found to decrease from 2.36 0.4 to 1.86 0.3mmol/L
(19%; P , 0.05). This TG plasma decrease is consistent with those
reported elsewhere (9, 10).
Short-chain acylcarnitines
The skeletal muscle acylcarnitine concentrations related to oxidative
metabolism of EAAs yielded the most dramatic changes in response
to EAAs 1 arginine challenge (Figure 2). Acylcarnitine metabo-
lites related to oxidation of leucine and isoleucine (i.e., isovaleryl-
carnitine and 2-methylbutyryl-carnitine) increased by 2200%
(P, 0.04) and 2400% (P, 0.008), respectively, in response to acute
EAAs 1 arginine intake (Figure 3). 3-Hydroxybutyryl-carnitine, a
metabolite of lysine metabolism, was also found to increase in re-
sponse to acute EAAs 1 arginine intake by 132% (P , 0.04). The
metabolic intermediates of valine oxidation, isobutyryl-carnitine
(136%; P , 0.01) and 3-hydroxy-isobutyryl-carnitine (95%; P , 0.05),
also increased in response to acute EAAs 1 arginine intake. All of
the aforementioned skeletalmuscle acylcarnitine basal concentrations
were unchanged after 8 wk of EAAs 1 arginine supplementation.
Before chronic supplementation, 3-hydroxy-isovaleryl-carnitine
(3MC4OH), an intermediate of oxidative metabolism of leucine,
was found to increase in response to acute EAAs 1 arginine in-
take (Figure 2; 70%; P, 0.02). Basal concentrations of 3MC4OH in-
creased with supplementation (250%; P , 0.05); however, there
was no observable effect of acute EAAs1 arginine intake on skeletal
muscle 3MC4OH concentrations after the 8-wk supplementation
period. It is notable that 3MC4OH does not have a direct route to
enter the TCA cycle, which may contribute to its accumulation in
muscle tissue (Figure 3).
Succinyl-carnitine (C4DC) showed a pattern of changes in re-
sponse to EAAs 1 arginine similar to 3MC4OH (Figure 4): in-
creased C4DC concentration in response to the initial acute
EAAs 1 arginine intake (40%; P , 0.05) and increased basal con-
centrations of C4DC after 8 wk of EAAs1 arginine supplementation
(250%; P, 0.05), but no increase in response to acute EAAs1 ar-
ginine intake after the 8-wk supplementation period. C4DC is a
metabolic intermediate that is downstream of oxidative metabolism
of a number of different amino acids (Figure 3). C4DC is also an-
aplerotic, acting to restore the TCA intermediate pool through a
succinyl-CoA-to-succinate pathway. Propionyl-carnitine (C3) is a
precursor to C4DC and is also considered anaplerotic. C3 was
found to increase in response to acute EAAs 1 arginine intake both
before (135%; P , 0.005) and after (143%; P , 0.01) the 8-wk sup-
plementation period (Figure 4). Basal concentrations of C3 showed a
modest increase (20%) in response to 8 wk of EAAs1 arginine sup-
plementation that did not quite reach significance (P , 0.06).
FIGURE 5 Differential response to acute EAAs 1 arginine intake before (week 0) and after (week 8) chronic EAAs 1 arginine supplementation
in skeletal muscle concentrations of medium- and long-chain ACs; n = 6. Solid horizontal lines within the boxes represent the median
values. *P , 0.05 (paired t test). AC, acylcarnitine; EAA, essential amino acid.
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Skeletal muscle concentrations of acetyl-carnitine (C2) were not
found to be increased either in response to acute EAAs 1 arginine
intake or to 8 wk of supplementation (Figure 4).
Medium- and long-chain acylcarnitines
Skeletal muscle medium-chain (C4–C10) and long-chain (C14 and
C18) acylcarnitine concentrations did not change significantly in re-
sponse to acute EAAs 1 arginine intake either before or after the
supplementation period (Figure 5). Basal skeletal muscle medium-
chain acylcarnitine concentrations also did not show any changes
in response to 8 wk of EAAs 1 arginine supplementation (Figure 5).
The basal concentrations of myristoyl-carnitine (C14; 90% increase;
P , 0.05) and stearoyl-carnitine (C18; 120% increase; P , 0.01)
were found to increase in response to 8 wk of EAAs 1 arginine
supplementation (Figure 5).
Organic acids
TCA intermediate concentrations in skeletal muscle were unchanged
by acute EAAs 1 arginine intake both before and after the 8-wk
EAAs1 arginine supplementation period (Supplemental Figure 1).
Although the basal skeletal muscle concentrations of fumarate and
malate increased by 44% (P , 0.01) and 115% (P , 0.002) (Figure
6), respectively, in response to 8 wk of EAAs1 arginine supplemen-
tation, there was no increase in the total sum of TCA intermediates
(Supplemental Figure 2). A 32% increase in lactate in skeletal
muscle (P , 0.04) was observed after the 8-wk supplementation
period. Muscle lactate and pyruvate concentrations were only
found to increase in response to acute EAAs 1 arginine intake
after, not before, 8 wk of chronic EAAs 1 arginine supplementa-
tion (Figure 7).
Discussion
Targeted metabolomic analysis of skeletal muscle biopsy samples
obtained from hypertriglyceridemic older adults receiving EAAs 1
arginine both through acute intake and chronically for 8 wk showed
altered acylcarnitine and organic acid profiles. Acute EAAs1 arginine
intake yielded increases in metabolic acylcarnitine intermedi-
ates of metabolism of EAA components, particularly BCAA catabolic
intermediates, in skeletal muscle. The leucine metabolite most
directly associated with 3MC4OH, b-hydroxy-b-methylbutyrate,
FIGURE 6 Effects of 8 wk of EAAs 1 arginine supplementation on basal skeletal muscle concentrations of TCA intermediates (in nanograms
per milligram); n = 6. Late-stage TCA intermediates malate and fumarate were increased after 8 wk of supplementation (dark-gray boxes)
relative to initial concentrations (white boxes). Solid horizontal lines within the boxes represent the median values. **P, 0.01 (paired t test). CA, citrate;
EAA, essential amino acid; FA, fumarate; iCA, isocitrate; MA, malate; OA, oxaloacetate; SA, succinate; TCA, tricaboxylic acid; aKG, a-ketoglutarate.
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has been implicated in the maintenance of muscle mass (20), and
the increase in 3MC4OH may be related to a signaling pathway–
inhibiting muscle protein breakdown. The acute EAAs 1 arginine
intake–mediated increase in 3-hydroxy-isobutyryl-carnitine is notable
for its structural relation to 3-hydroxy-isobutyric acid, a metabolite of
valine, which has been found to stimulate endothelial transport of
FFAs, leading to lipid accumulation in skeletal muscle in mice (21).
Eight weeks of EAAs 1 arginine supplementation resulted in
increased basal concentrations of long-chain acylcarnitines. Previous
in vitro studies found that long-chain acylcarnitine accumulation in
muscle tissue elicits an insulin-resistant response (22). In addition,
8-wk EAAs1 arginine supplementation resulted in increased skeletal
muscle concentrations of anaplerotic acylcarnitines C4DC and C3.
Similar observations have been made in mice fed a high-fat diet with
BCAAs (23) and are consistent with a hypothesis that increased
BCAA catabolism leads to accumulation of FA oxidation intermediates.
Although the total amount of TCA intermediates remained un-
changed by 8 wk of supplementation, a shift toward late-stage
TCA intermediates was observed. This distribution toward late-
stage TCA intermediates is often reflective of anaplerosis (24,
25); and when considered alongside the increases in skeletal muscle
anaplerotic acylcarnitines, this suggests that anaplerosis was in-
creased after the 8-wk EAAs 1 arginine supplementation period.
The increased skeletal muscle lactate concentrations after the
8-wk period may arise from increased demand for NAD+ required
for increased reliance on b-oxidation (26). Acute EAAs 1 arginine
intake after the 8-wk supplementation period yielded increased
skeletal muscle concentrations of lactate and pyruvate only after
the 8-wk supplementation period. This suggests that there are
alterations in energymetabolism arising from chronic EAAs1 arginine
supplementation that do not present in the fasted state, but be-
come apparent when amino acids are ingested acutely.
This investigation has several factors that may limit the conclu-
sions. First, there was no placebo control used; therefore, placebo
effects could be a possible explanation for our observations. How-
ever, the previously published controlled studies give us reason to
believe that this is not a placebo effect (9, 10). Second, as a pilot
study, the sample size was small (n = 6); thus, the results are at in-
creased risk of arising from type I error. Despite these limitations,
we have a high degree of confidence in our results. First, the acute
experiment was conducted both before and after the chronic pe-
riod and the observed effects were confirmed in all but 2 of the
30metabolites measured (Figure 7), giving us a high degree of con-
fidence that these results do not arise from type I error. The main
findings that resulted from 8 wk of chronic supplementation were
observed in 2 independent metabolites, increasing our confidence
that these did not arise from type I error: the increased long-chain
acylcarnitine concentrations were observed in both C14 and C18
and the increased late-stage TCA intermediates were observed
in both fumarate and malate. The results described herein are sig-
nificant and fit within the larger context of our understanding of
the physiologic effects of EAAs 1 arginine supplementation.
Acknowledgments
The authors’ responsibilities were as follows—BJM, RRW, and EB:
designed the research; BJM, NMH, EC, I-YK, SS, and GA: conducted
the research; BJM: analyzed the data and had primary responsibility
for the final content; BJM and NMH: wrote the manuscript; and all
authors: read and approved the final manuscript.
References
1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005.
Natl Vital Stat Rep 2008;56:1–120.
2. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and
cardiovascular risk reduction. Clin Ther 2007;29:763–77.
3. Cheng AYY, Leiter LA. Implications of recent clinical trials for the
National Cholesterol Education Program Adult Treatment Panel III
guidelines. Curr Opin Cardiol 2006;21:400–4.
4. National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). Third report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III): final report. Circulation 2002;106:3143–421.
5. Parks EJ, Hellerstein MK. Carbohydrate-induced
hypertriacylglycerolemia: historical perspective and review of
biological mechanisms. Am J Clin Nutr 2000;71:412–33.
6. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J,
Williams T, Williams M, Gracely EJ, Stern L. A low-carbohydrate as
compared with a low-fat diet in severe obesity. N Engl JMed 2003;348:
2074–81.
FIGURE 7 Skeletal muscle lactate and pyruvate concentrations in
response to acute EAA intake before (week 0) and after (week 8)
chronic EAA supplementation; n = 6. Solid horizontal lines within
the boxes represent the median values. *P , 0.05, **P , 0.01, and
***P , 0.001 (paired t test). EAA, essential amino acid.
CURRENT DEVELOPMENTS IN NUTRITION
Muscle metabolic response to essential amino acids 7
Downloaded from https://academic.oup.com/cdn/article-abstract/1/11/e002071/4735248
by Roehampton University user
on 31 January 2018
7. Bortolotti M, Maiolo E, Corazza M, Van Dijke E, Schneiter P, Boss A,
Carrel G, Giusti V, Leˆ KA, Quo Chong DG, et al. Effects of a whey
protein supplementation on intrahepatocellular lipids in obese female
patients. Clin Nutr 2011;30:494–8.
8. Oda H. Functions of sulfur-containing amino acids in lipid metabolism.
J Nutr 2006;136(Suppl):1666S–9S.
9. Børsheim E, Bui QU, Tissier S, Cree MG, Rønsen O, Morio B, Ferrando
AA, Kobayashi H, Newcomer BR, Wolfe RR. Amino acid
supplementation decreases plasma and liver triacylglycerols in elderly.
Nutrition 2009;25:281–8.
10. Coker RH, Deutz NE, Schutzler S, Beggs M, Miller S, Wolfe RR,
Wei J. Nutritional supplementation with essential amino acids
and phytosterols may reduce risk for metabolic syndrome and
cardiovascular disease in overweight individuals with mild
hyperlipidemia. J Endocrinol Diabetes Obes 2015;3:1069.
11. Baker PR, Boyle KE, Koves TR, Ilkayeva OR, Muoio DM, Houmard JA,
Friedman JE. Metabolomic analysis reveals altered skeletal muscle
amino acid and fatty acid handling in obese humans. Obesity (Silver
Spring) 2015;23:981–8.
12. Lerin C, Goldfine AB, Boes T, Liu M, Kasif S, Dreyfuss JM, De Sousa-
Coelho AL, Daher G, Manoli I, Sysol JR, et al. Defects in muscle
branched-chain amino acid oxidation contribute to impaired lipid
metabolism. Mol Metab 2016;5:926–36.
13. Guda P, Guda C, Subramaniam S. Reconstruction of pathways
associated with amino acid metabolism in human mitochondria.
Genomics Proteomics Bioinformatics 2007;5:166–76.
14. Melser S, Lavie J, Be´nard G. Mitochondrial degradation and energy
metabolism. Biochim Biophys Acta 2015;1853:2812–21.
15. Roe DS, Roe CR, Brivet M, Sweetman L. Evidence for a short-chain
carnitine-acylcarnitine translocase in mitochondria specifically related
to the metabolism of branched-chain amino acids. Mol Genet Metab
2000;69:69–75.
16. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR.
A high proportion of leucine is required for optimal stimulation of the
rate of muscle protein synthesis by essential amino acids in the elderly.
Am J Physiol Endocrinol Metab 2006;291:E381–7.
17. Marquis BJ, Louks HP, Bose C, Singh SP. A new derivatization reagent
for high performance liquid chromatography mass spectrometry
analysis of biological organic acids. Chromatographia. In press.
18. Tan B, Lu ZH, Dong SC, Zhao GS, Kuo MS. Derivatization of the
tricarboxylic acid intermediates with O-benzylhydroxylamine for
liquid chromatography-tandem mass spectrometry detection. Anal
Biochem 2014;465:134–47.
19. Maeda Y, Ito T, Suzuki A, Kurono Y, Ueta A, Yokoi K, Sumi S, Togari
H, Sugiyama N. Simultaneous quantification of acylcarnitine isomers
containing dicarboxylic acylcarnitines in human serum and urine by
high-performance liquid chromatography/electrospray ionization
tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21:
799–806.
20. Wu H, Xia Y, Jiang J, Du H, Guo X, Liu X, Li C, Huang G, Niu K. Effect
of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss
in older adults: a systematic review and meta-analysis. Arch Gerontol
Geriatr 2015;61:168–75.
21. Jang C, Oh SF, Wada S, Rowe GC, Liu L, ChanMC, Rhee J, Hoshino A,
Kim B, Ibrahim A, et al. A branched-chain amino acidmetabolite drives
vascular fatty acid transport and causes insulin resistance. Nat Med
2016;22:421–6.
22. Aguer C, McCoin CS, Knotts TA, Thrush AB, Ono-Moore K,
McPherson R, Dent R, Hwang DH, Adams SH, Harper ME.
Acylcarnitines: potential implications for skeletal muscle insulin
resistance. FASEB J 2015;29:336–45.
23. Newgard CB, An J, Bain JR,MuehlbauerMJ, Stevens RD, Lien LF, Haqq
AM, Shah SH, Arlotto M, Slentz CA, et al. A branched-chain amino acid-
related metabolic signature that differentiates obese and lean humans
and contributes to insulin resistance. Cell Metab 2009;9:311–26.
24. Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and
cataplerosis for citric acid cycle function. J Biol Chem 2002;277:
30409–12.
25. Brunengraber H, Roe CR. Anaplerotic molecules: current and future.
J Inherit Metab Dis 2006;29:327–31.
26. Kane DA. Lactate oxidation at the mitochondria: a lactate-malate-
aspartate shuttle at work. Front Neurosci 2014;8:366.
CURRENT DEVELOPMENTS IN NUTRITION
8 Marquis et al.
Downloaded from https://academic.oup.com/cdn/article-abstract/1/11/e002071/4735248
by Roehampton University user
on 31 January 2018
